Voyager Therapeutics, Inc. (NASDAQ:VYGR)‘s stock had its “hold” rating reaffirmed by stock analysts at Chardan Capital in a research report issued on Sunday, September 10th.
Other analysts have also recently issued research reports about the company. Evercore ISI assumed coverage on Voyager Therapeutics in a research report on Wednesday, August 16th. They set an “outperform” rating and a $12.00 price objective for the company. Zacks Investment Research cut Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. ValuEngine cut Voyager Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, July 28th. BidaskClub upgraded Voyager Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 13th. Finally, Cowen and Company reiterated a “buy” rating on shares of Voyager Therapeutics in a research report on Tuesday, August 8th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the stock. Voyager Therapeutics presently has a consensus rating of “Hold” and an average price target of $23.43.
Shares of Voyager Therapeutics (NASDAQ VYGR) opened at 17.50 on Friday. The stock has a 50 day moving average of $10.74 and a 200-day moving average of $10.41. The stock’s market capitalization is $470.80 million. Voyager Therapeutics has a 52 week low of $8.10 and a 52 week high of $18.25.
Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Tuesday, August 8th. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.11). The company had revenue of $1.18 million for the quarter, compared to analysts’ expectations of $3.27 million. Voyager Therapeutics had a negative return on equity of 46.15% and a negative net margin of 712.22%. On average, equities research analysts expect that Voyager Therapeutics will post ($2.84) EPS for the current year.
In other news, insider Bernard Ravina sold 5,490 shares of the business’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $10.00, for a total transaction of $54,900.00. Following the completion of the sale, the insider now owns 17,157 shares in the company, valued at approximately $171,570. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 27,450 shares of company stock valued at $321,769 in the last quarter. Company insiders own 6.00% of the company’s stock.
Several large investors have recently modified their holdings of VYGR. DAFNA Capital Management LLC grew its holdings in shares of Voyager Therapeutics by 187.2% during the 2nd quarter. DAFNA Capital Management LLC now owns 204,808 shares of the company’s stock worth $1,835,000 after purchasing an additional 133,488 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Voyager Therapeutics by 232.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 98,128 shares of the company’s stock worth $879,000 after purchasing an additional 68,574 shares during the period. HarbourVest Partners LLC purchased a new stake in shares of Voyager Therapeutics during the 2nd quarter worth about $400,000. Wells Fargo & Company MN grew its holdings in shares of Voyager Therapeutics by 114.4% during the 1st quarter. Wells Fargo & Company MN now owns 83,577 shares of the company’s stock worth $1,107,000 after purchasing an additional 44,599 shares during the period. Finally, Northern Trust Corp lifted its position in Voyager Therapeutics by 26.8% during the 2nd quarter. Northern Trust Corp now owns 133,571 shares of the company’s stock worth $1,197,000 after acquiring an additional 28,222 shares in the last quarter. Institutional investors and hedge funds own 40.70% of the company’s stock.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with our FREE daily email newsletter.